VEGF inhibition, hypertension, and renal toxicity

Area of Science:

• Oncology
• Pharmacology
• Vascular Biology

Background:

• Anti-angiogenic agents targeting vascular endothelial growth factor (VEGF) are integral to treating advanced solid tumors, including renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors.
• These therapies include monoclonal antibodies like bevacizumab and tyrosine kinase inhibitors (TKIs) that target VEGF and its receptors.
• Common adverse effects are vascular, linked to anti-VEGF activity, necessitating a thorough understanding for effective management.

Purpose of the Study:

• To review the common vascular adverse effects of anti-angiogenic therapies.
• To elucidate the underlying mechanisms of these side effects.
• To emphasize the importance of prompt diagnosis and management for improved patient outcomes.

Main Methods:

• Review of literature on anti-angiogenic agents and their adverse vascular effects.
• Analysis of mechanisms linking anti-VEGF activity to specific toxicities.
• Synthesis of information for clinical application in managing side effects.

Main Results:

• Common adverse vascular effects include hypertension, renal vascular injury (proteinuria, thrombotic microangiopathy), and congestive heart failure.
• These effects are directly or indirectly related to the inhibition of VEGF signaling.
• Understanding these mechanisms aids in early detection and intervention.

Conclusions:

• Knowledge of anti-angiogenic agent side effects is vital for oncologists and healthcare providers.
• Timely diagnosis and management of vascular toxicities can minimize morbidity and mortality.
• Effective side effect management can improve patient quality of life and treatment adherence for underlying malignancies.